HtmlToText
advanced accelerator applications bridging science with life about us about us history our business our sites executive committee board of directors corporate social responsibility code of conduct products products home smpc & pi research & development r&d home pipeline clinical trials partnering scientific publications & presentations theragnostic platform ephoran multi imaging solutions investor relations ir home news & events corporate governance financial information shareholder services press room press room home press releases conferences & events photo gallery nuclear medicine about nuclear medicine diagnostics therapy theragnostics glossary contact us careers search for: -- -- our ambition at advanced accelerator applications is to turn scientific findings into life enhancing applications. flash news -- advanced accelerator applications announces first patients dosed in two clinical studies with psma-r2 for prostate cancer second theragnostic program for oncology enters the clinic - june 2018 aaa today announced that the first patients have been dosed in two phase i/ii clinical studies of radiolabeled psma-r2, a urea-based ligand of prostate-specific membrane antigen (psma), which is commonly expressed on prostate cancer cells. a worldwide presence aaa operates in belgium, canada, france, germany, israel, italy, the netherlands, poland, portugal, spain, switzerland, uk and usa while its distribution network covers more than 30 countries. please point to any of the locations to pull up specific details about each facility. read more products advanced accelerator applications (aaa) develops, produces and commercializes molecular nuclear medicine, diagnostic and therapeutic products in the fields of oncology (cancer), neurology, cardiology and infectious & inflammatory diseases. read more pipeline we are developing a pipeline of theragnostic pairings for oncology indications. aaa’s theragnostic platform involves radiolabeling a targeting molecule with either gallium ga 68 for diagnostic use, or lutetium lu 177 for therapy. read more molecular nuclear medicine making personalised treatment a reality. aaa is a european leader in the production and commercialization of pet (positron emission tomography) and spect (single photon emission tomography) radiopharmaceuticals and is able to produce and deliver both commercial drugs and research products. discover our documentary about molecular nuclear medicine and cancer. molecular nuclear medicine with a 22’ documentary from the history of radioactivity and cancer to the most modern theragnostic techniques. you will understand how spect and pet work, and how radio metabolic therapy can treat cancer. search for: homepage contact us careers site map disclaimer privacy policy © 2014-20 advanced accelerator applications - all rights reserved contact-page info@adacap.com x we inform you that the personal data you provide by sending this e-mail will be processed in compliance with articles 13 and 14 of regulation (eu) 2016/679 (gdpr) as referred to in the privacy policy on our website and which recalls the confidentiality obligations that inspire our company's activity in order to be able to respond quickly and comprehensively to your request. the processing of your personal data will be carried out using appropriate tools to ensure the security and confidentiality of the aforementioned data. the methods of processing of data referred in this notice to here provide for applies for the use of manual, computerized and telematic tools. your data will be processed by employees and / or collaborators of aaa duly appointed for processing. furthermore, aaa is part of a multinational group, therefore it may be that your personal data are transferred to other countries, even outside the european union, to parent companies, subsidiaries or affiliates, as well as to external service companies, even if only for technical-it reasons. in these cases we will proceed to their transfer only in the presence of the provision of your consent. the optional, explicit and voluntary sending of e-mail address or other data entered in the contact form to the official addresses indicated on this site entails the subsequent acquisition of the sender's e-mail address necessary to respond to requests, as well as any other personal data entered. specific summary information could be progressively reported or displayed on the pages of the website prepared for particular services on request. by sending and / or requesting contact via e-mail or form, you are also consenting to receive aaa newsletter and non-commercial information. the user confers the widest indemnity with respect to any objection, claim request for compensation for damage from treatment that should be received by the data controller from any third party concerned due to the provision of data indicated by the user in violation of the rules on protection of the personal data applicable according to the gdpr 2016/679. the regulation (eu) 2016/679 includes measures to protect and guarantee your rights, in particular, the interested party has the right at any time to obtain confirmation of the existence of personal data concerning him/her and to know its content and origin, verify its accuracy or request its integration or updating, or rectification. it also has the right to request the cancellation, transformation into anonymous form or blocking of data processed in violation of the law, as well as to oppose in any case, for legitimate reasons, to their processing. you may exercise these rights at any time by contacting us at: dpo@adacap.com to get more information about the website privacy policy, click here having read the above notice, i consent to the processing of personal data, to any communication to the subjects listed in the notice for the purposes and with the methods indicated and to the transfer abroad, even in countries outside the european union. i accept your name your email message cancel contact-page pharmacovigilance_aaa@adacap.com x we inform you that the personal data you provide by sending this e-mail will be processed in compliance with articles 13 and 14 of regulation (eu) 2016/679 (gdpr) as referred to in the privacy policy on our website and which recalls the confidentiality obligations that inspire our company's activity in order to be able to respond quickly and comprehensively to your request. the processing of your personal data will be carried out using appropriate tools to ensure the security and confidentiality of the aforementioned data. the methods of processing of data referred in this notice to here provide for applies for the use of manual, computerized and telematic tools. your data will be processed by employees and / or collaborators of aaa duly appointed for processing. furthermore, aaa is part of a multinational group, therefore it may be that your personal data are transferred to other countries, even outside the european union, to parent companies, subsidiaries or affiliates, as well as to external service companies, even if only for technical-it reasons. in these cases we will proceed to their transfer only in the presence of the provision of your consent. the optional, explicit and voluntary sending of e-mail address or other data entered in the contact form to the official addresses indicated on this site entails the subsequent acquisition of the sender's e-mail address necessary to respond to requests, as well as any other personal data entered. specific summary information could be progressively reported or displayed on the pages of the website prepared for particular services on request. by sending and / or requesting contact via e-mail or form, you are also consenting to receive aaa newsletter and non-commercial information. the user confers the widest indemnity with respect to any objection, claim request for compensation for damage from treatment that should be received by the data controller from
Informations Whois
Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;
Domain Name: ADACAP.COM
Registry Domain ID: 85912441_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.tucows.com
Registrar URL: http://www.tucowsdomains.com
Updated Date: 2016-03-08T10:05:15Z
Creation Date: 2002-04-24T09:42:13Z
Registry Expiry Date: 2019-04-24T09:42:13Z
Registrar: Tucows Domains Inc.
Registrar IANA ID: 69
Registrar Abuse Contact Email:
Registrar Abuse Contact Phone:
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: DNS.TECHNORAIL.COM
Name Server: DNS2.TECHNORAIL.COM
Name Server: DNS3.ARUBADNS.NET
Name Server: DNS4.ARUBADNS.CZ
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-09-26T11:13:54Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
REGISTRAR Tucows Domains Inc.
SERVERS
SERVER com.whois-servers.net
ARGS domain =adacap.com
PORT 43
TYPE domain
RegrInfo
DOMAIN
NAME adacap.com
CHANGED 2016-03-08
CREATED 2002-04-24
STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
NSERVER
DNS.TECHNORAIL.COM 62.149.128.2
DNS2.TECHNORAIL.COM 62.149.132.2
DNS3.ARUBADNS.NET 95.110.220.5
DNS4.ARUBADNS.CZ 81.2.199.73
REGISTERED yes
Go to top
adacap.com rapport :
Visitez le site